STUDY OBJECTIVES: Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and cataplexy. The association with human leukocyte antigen (HLA)-DQB1*0602 and T-cell receptor alpha locus suggests that autoimmunity plays a role in narcolepsy. A recent study reported an increased prevalence of autoantibodies against Tribbles homolog 2 (TRIB2) in patients with narcolepsy. To replicate this finding, we examined anti-TRIB2 autoantibodies in Japanese patients with narcolepsy. DESIGN: We examined anti-TRIB2 autoantibodies against a full-length [35S]-labeled TRIB2 antigen in Japanese patients with narcolepsy-cataplexy (n = 88), narcolepsy without cataplexy (n = 18), and idiopathic hypersomnia with long sleep time (n = 11). The results were compared to Japanese healthy controls (n = 87). Thirty-seven healthy control subjects were positive for HLA-DRB1*1501-DQB1*0602. We also examined autoantibodies against another Tribbles homolog, TRIB3, as an experimental control. MEASUREMENTS AND RESULTS: Autoantibodies against TRIB2 were found in 26.1% of patients with narcolepsy-cataplexy, a significantly higher prevalence than the 2.3% in healthy controls. We found that anti-TRIB3 autoantibodies were rare in patients with narcolepsy and showed no association with anti-TRIB2 indices. No significant correlation was found between anti-TRIB2 positivity and clinical information. CONCLUSIONS: We confirmed the higher prevalence and specificity of anti-TRIB2 autoantibodies in Japanese patients with narcolepsy-cataplexy. This suggests a subgroup within narcolepsy-cataplexy might be affected by an anti-TRIB2 autoantibody-mediated autoimmune mechanism.
STUDY OBJECTIVES:Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and cataplexy. The association with humanleukocyte antigen (HLA)-DQB1*0602 and T-cell receptor alpha locus suggests that autoimmunity plays a role in narcolepsy. A recent study reported an increased prevalence of autoantibodies against Tribbles homolog 2 (TRIB2) in patients with narcolepsy. To replicate this finding, we examined anti-TRIB2 autoantibodies in Japanese patients with narcolepsy. DESIGN: We examined anti-TRIB2 autoantibodies against a full-length [35S]-labeled TRIB2 antigen in Japanese patients with narcolepsy-cataplexy (n = 88), narcolepsy without cataplexy (n = 18), and idiopathic hypersomnia with long sleep time (n = 11). The results were compared to Japanese healthy controls (n = 87). Thirty-seven healthy control subjects were positive for HLA-DRB1*1501-DQB1*0602. We also examined autoantibodies against another Tribbles homolog, TRIB3, as an experimental control. MEASUREMENTS AND RESULTS: Autoantibodies against TRIB2 were found in 26.1% of patients with narcolepsy-cataplexy, a significantly higher prevalence than the 2.3% in healthy controls. We found that anti-TRIB3 autoantibodies were rare in patients with narcolepsy and showed no association with anti-TRIB2 indices. No significant correlation was found between anti-TRIB2 positivity and clinical information. CONCLUSIONS: We confirmed the higher prevalence and specificity of anti-TRIB2 autoantibodies in Japanese patients with narcolepsy-cataplexy. This suggests a subgroup within narcolepsy-cataplexy might be affected by an anti-TRIB2 autoantibody-mediated autoimmune mechanism.
Authors: N Kerkar; Y Ma; M Hussain; L Muratori; C Targett; R Williams; F B Bianchi; G Mieli-Vergani; D Vergani Journal: J Immunol Methods Date: 1999-03-04 Impact factor: 2.303
Authors: C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot Journal: Nat Med Date: 2000-09 Impact factor: 53.440
Authors: E Mignot; L Lin; W Rogers; Y Honda; X Qiu; X Lin; M Okun; H Hohjoh; T Miki; S Hsu; M Leffell; F Grumet; M Fernandez-Vina; M Honda; N Risch Journal: Am J Hum Genet Date: 2001-02-13 Impact factor: 11.025
Authors: T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel Journal: Neuron Date: 2000-09 Impact factor: 17.173
Authors: Yves Dauvilliers; Jacques Montplaisir; Valéerie Cochen; Alex Desautels; Mali Einen; Ling Lin; Minae Kawashima; Sophie Bayard; Christelle Monaca; Michel Tiberge; Daniel Filipini; Asit Tripathy; Bich Hong Nguyen; Suresh Kotagal; Emmanuel Mignot Journal: Sleep Date: 2010-11 Impact factor: 5.849
Authors: Jasbir Dalal; Jee Hoon Roh; Susan E Maloney; Afua Akuffo; Samir Shah; Han Yuan; Brie Wamsley; Wendell B Jones; Cristina de Guzman Strong; Paul A Gray; David M Holtzman; Nathaniel Heintz; Joseph D Dougherty Journal: Genes Dev Date: 2013-02-21 Impact factor: 11.361
Authors: Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley Journal: Physiol Rev Date: 2012-07 Impact factor: 37.312
Authors: Sona Nevsimalova; Juraj Pisko; Jitka Buskova; David Kemlink; Iva Prihodova; Karel Sonka; Jelena Skibova Journal: J Neurol Date: 2012-10-16 Impact factor: 4.849